

EARN

FREE LIVEINTERACTIVEONLINE

AUGUST 21-24, 2020



www.HEARTiNDIABETES.com























4th Heart in Diabetes Welcome Letter (Virtual):

We invite you to join us for the 4th Annual Heart in Diabetes (HiD) Live Interactive Online Medical Conference to be held from August 21-24, 2020. Following the conference, all content will be available on demand for 90 days. 4th HiD live virtual registration is FREE. Click here to register. Attendees may earn up to 28 FREE CME

Heart in Diabetes is a medical conference representing an educational initiative, which is a combined effort of cardiologists and endocrinologists. To date, the HiD congress has been a rousing success, with progressive growth of participants and impressive evaluations. Overall, attendees at the 3rd annual conference rated the congress a 3.04 out of 4 in terms of overall quality, educational content, and positive impact on knowledge and professional effectiveness.

The 4th Annual Heart in Diabetes (HiD) will convene expert faculty and practicing clinicians in a one-of-a-kind virtual scientific conference to share knowledge and best practices for managing patients with diabetes, heart disease, and various cardiometabolic conditions. Since 2017, this unique forum has enabled clinicians to improve care for patients with diabetes and obesity who have cardiovascular disease and/or chronic kidney disease, often with heart failure. These disorders share many pathological features and often occur in the same individual. Until recently, however, they were managed by different specialists with varying clinical priorities and goals. The strength of HiD is the promotion and development of cross-discipline approaches to the management of these conditions.

Recent trials have demonstrated cardiovascular benefits from agents that control glycemia, lipids, blood pressure, and inflammation in people with diabetes. However, among practicing professionals, including experts, there is a gap in understanding the implications of these new developments in disease management. The conference examines the newest outcome data and develops suggestions for clinicians and recommendations on the proper implementation of the studies results in practice.

HiD is an all "state-of-the-art" clinical program. The agenda will feature an award presentation "Luminary in Cardiometabolic Medicine" to Dr. Eugene Braunwald, who will provide a keynote lecture. This program provides up-to-date clinical science of the Heart in Diabetes through a multidisciplinary interpretation of outcome data and its implications for practice; this from cardiology, endocrine/diabetes, and nephrology points of view. The virtual conference will include joint sessions with Circulation and JACC (Journal of the American College of Cardiology). In addition, the conference will cover sessions on COVID-19 in Diabetes I CVD, Women I CVD, Contemporary Concepts I Management of DM & ASVCD, The Kidney, Technology & Digital Health, Lipids, Antithrombotics in Diabetes, The Liver, Managing Hyperglycemia, Treatment of Diabetes, Heart Failure and will cover Guidelines and Practice Recommendations. The 4th HiD will also feature several virtual abstract presentations from scientists and researchers around the world as well as several Non-CME Industry Supported presentations.



Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE



Mikhail N. Kosiborod, MD, FACC, FAHA

Heart in Diabetes (HiD) Scientific Committee

Yehuda Handelsman, MD *Chair*Tarzana, California

Mikhail N. Kosiborod, MD Chair

Kansas City, Missouri

Deepak L. Bhatt, MDBoston, Massachusetts

Zachary T. Bloomgarden, MD

New York, New York

Biykem Bozkurt, MD, PhD Houston, Texas

Matthew J. Budoff, MD Los Angeles, California

Javed Butler, MD Jackson, Mississippi **David Cherney, MD, PhD** Toronto, Canada

Robert J. Chilton, DO San Antonio, Texas

Mark E. Cooper, AO, PhD Melbourne, Australia

Michael H. Davidson, MD Chicago, Illinois

Ralph A. DeFronzo, MD San Antonio, Texas

Stefano Del Prato, MD Pisa, Italy

Daniel Einhorn, MD San Diego, California

Michael E. Farkouh, MD Toronto, Canada **Sergio Fazio, MD, PhD**Portland, Oregon

Vivian A. Fonseca, MD New Orleans, Louisiana

Peter J. Grant, MD Leeds, United Kingdom

George Grunberger, MD Bloomfield Hills, Michigan

Mansoor Husain, MD Toronto, Canada

Silvio E. Inzucchi, MD

New Haven, Connecticut **Paul S. Jellinger, MD**Hollywood, Florida

Mark Kearney, MD Leeds, United Kingdom Lawrence A. Leiter, MDCM Toronto, Canada

Norman E. Lepor, MD Los Angeles, California

Derek LeRoith, MD, PhD New York, New York

Christos S. Mantzoros, MD, PhD

Boston, Massachusetts

Nikolaus Marx, MD Aachen, Germany

Darren K. McGuire, MD Dallas, Texas

Christian W. Mende, MD San Diego, California Richard E. Pratley, MD Orlando, Florida

Kausik Ray, MD, MPhil London, United Kingdom

Peter Reaven, MD Phoenix, Arizona

Benjamin M. Scirica, MDBoston, Massachusetts

Laurence Sperling, MD Atlanta, Georgia

Matthew R. Weir, MD Baltimore, Maryland

PROGRAM DESCRIPTION:

This CME conference is a unique medical meeting that brings world-renowned clinical leaders in diabetes and cardiovascular disease and practicing clinicians together to improve the care of patients at a high risk of cardiovascular, metabolic, and kidney diseases. This program is designed to evaluate the clinical science aspects of diabetes, obesity, and CVD, focusing on the heart and kidney in diabetes. The goal is to develop appropriate, comprehensive clinical management plans aligning endocrinologists, cardiologists, nephrologists and all other interested clinicians in their understandings of the impact of diabetes and CVD outcome trials on the clinical management of these very high-risk patients.

PROGRAM OBJECTIVES: Upon completion of this meeting, participants should be able to:

- Discuss the role of incretins in the management of obesity, diabetes, and its complications
- Evaluate the evidence supporting the use of SGLT2 inhibitors and GLP1-RAs to reduce cardiovascular mortality in patients with T2D
- Evaluate the evidence supporting the use of SGLT2 inhibitors for HF prevention
- Evaluate the extent of vascular disease in diabetes and cardiometabolic syndrome
- Evaluate the extent of macro and microvascular disease in diabetes and obesity
- Provide comprehensive management of diabetes, addressing obesity, hypertension, and dyslipidemia as well as glucose
- Discuss changes in lipid management guidelines
- Evaluate the impact on the clinical practice of new CV outcome trials in patients with diabetes, including CANVAS, LEADER, SUSTAIN 6, and EMPA-REG
- Evaluate the impact on the clinical practice of lipid CV outcome trials, including IMPROVE-IT, FOURIER, REDUCE-IT, ODYSSEY-Outcomes
- Implement the best practices for the management of HFrEF

- Describe the relationship between diabetes, obesity, and congestive heart failure
- Describe the role of PCSK9 in lipid elevations and their potential contributions to vascular disease
- Understand the mechanism of action of PCSK9 inhibitors and CETP inhibitors and their impact on CVD
- Design appropriate insulin-based therapeutic regimens for patients with type 2 diabetes
- Describe obesity management based on a complications-centric model
- Evaluate bariatric procedures and surgery as well as devices, and their effect on weight loss, hormones, and long-term outcomes
- Describe optimal use of glucose monitoring devices

TARGET AUDIENCE

This educational initiative is designed for endocrinologists, cardiologists, diabetologists, nephrologists, internists, family physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in the prevention and treatment of diabetes, obesity, cardiovascular disease, and associated conditions, as well as the effect of these conditions on health and society.

THE HID SCIENTIFIC COMMITTEE GRATEFULLY ACKNOWLEDGES

CORPORATE SUPPORT

Sapphire: **ESPERION**

Emeral: AMARIN • ASTRAZENECA • BI/LILLY

UNRESTRICTED EDUCATIONAL GRANTS

Premier Educator: ASTRAZENECA

Leader Educator: AMGEN

Major Educators: ABBOTT • PFIZER/MERCK ALLIANCE • NOVO NORDISK

Educator: LILLY USA • AMARIN PHARMA INC

PROGRAM 2020

11:40am — 12:00pm

12:00pm — 12:20pm

12:20pm — 12:40pm

Anti-thrombotic Therapy in Diabetes

Panel Discussion & Live Q&A

COMPASS

FRIDAY AUGUST 21, 2020

Richard C. Becker, MD

Deepak L. Bhatt, MD

Welcome & Introduction Yehuda Handelsman, MD ● Mikhail N. Kosiborod, MD

	Welcome & Introduction	Yehuda Handelsman, MD ● Mikhail N. Kosiborod, MD	
SESSION 1	COVID-19 IN DM & CVD Chair: Derek LeRoith, MD, PhD		
10:00am — 10:20am 10:20am — 10:40am 10:40am — 11:00am 11:00am — 11:20am 11:20am — 11:40am 11:40am — 12:00pm	Obesity, a Major Predictor of Mortality by COVID-19: Associations with DM & CVD and Implicate CVD Incidence & MOA in COVID-19: Vascular, Inflammatory & Thrombosis Implications Ongoing Research of COVID-19 Complications & Management - Focus on DARE-19 Diabetes and the COVID-19 Pandemic The Impact of COVID-19 on Cardiovascular Care & the Post-Pandemic Future of Cardiovascular Panel Discussion & Live Q&A	Mansoor Husain, MD Mikhail N. Kosiborod, MD Zachary Bloomgarden, MD	
SESSION 2	CONTEMPORARY CONCEPTS & MANAGEMENT OF DM & ASCVD Chair: Laurence Sperling, MD		
12:00pm — 12:20pm 12:20pm — 12:40pm 12:40pm — 1:00pm 1:00pm — 1:20pm	Epigenetic Modification to Reduce CVD in People with DM The Surgical Management of CAD in DM Update on CVOTs Panel Discussion & Live Q&A	Kausik Ray, MD Michael E. Farkouh, MD Michael H. Davidson, MD	
1:20PM – 2:05PM	PRODUCT THEATER Non-CME Industry Supported Session VASCEPA® (icosapent ethyl): Elevating the Standard of Care Supported by: Amarin	Yehuda Handelsman, MD	
SESSION 3	CONTROVERSIES IN LIPID MANAGEMENT Chair: Paul S. Jellinger, MD ● Kausik Ray, MD		
2:05pm — 2:25pm 2:25pm — 2:45pm	"Back to the Future" with Lipid Therapy Should High Triglycerides Be Managed in Addition to a Statin & EPA?	Norman E. Lepor, MD Sergio Fazio, MD, PhD	
2:45pm - 3:00pm 3:00pm - 3:15pm 3:15pm - 3:20pm 3:20pm - 3:25pm 3:25pm - 3:45pm	EATMENT WITH PCSK9I BE RESERVED FOR LDL > 100 Yes No Rebuttal Rebuttal Panel, Q&A, Audience Voting	Jennifer G. Robinson, MD Steven E. Nissen, MD	
SESSION 4	HEART IN DIABETES WITH CIRCULATION Chairs: Biykem Bozkurt, MD, PhD		
3:45pm — 3:50pm 3:50pm — 4:05pm 4:05pm — 4:20pm 4:20pm — 4:35pm 4:35pm — 4:50pm 4:50pm — 5:05pm 5:05pm — 5:25pm	Introduction GLP1ra Exenatide and Heart Failure Outcomes The Diabetes Paradox in Aortic Aneurysm Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of CVD in T1DM Heart Failure Risk Stratification and Efficacy of SGLT2i in Patients with T2DM Sugar and Artificially-Sweetened Beverages and CVD Risk - Reason for Concern? Panel, Live Q&A	Biykem Bozkurt, MD, PhD Robert J. Mentz, MD Joshua Beckman, MD Myra A. Lipes, MD Benjamin M. Scirica, MD Alice H. Lichtenstein, D.Sc.	
5:25PM - 6:15PM	DAY 1 SUMMARY, LIVE Q&A Panel: Biykem Bozkurt, MD, PhD • Vivian Fonseca, MD Derek Leroith, MD, PhD • Laurence Sperling, MD	● Yehuda Handelsman, MD ● Norman Lepor, MD ●	
		SATURDAY AUGUST 22, 2020	
SESSION 5	WOMEN & CVD Chairs: Norman E. Lepor, MD		
10:00am — 10:20am 10:20am — 10:40am 10:40am — 11:00am 11:00am — 11:20am	Cardiovascular Disease Risk Reduction in Menopausal Women Gender Differences in Cardiovascular Imaging Sex Differences in DM & CVD Across Outcome Studies Panel Discussion & Live Q&A	Gina P. Lundberg, MD Matthew J. Budoff, MD Neha J. Pagidipati, MD	
SESSION 6	ADVANCES IN ANTI-THROMBOTICS IN DIABETES Chairs: Deepak L. Bhatt, MD		
11:20am — 11:40am	Insights on Anti-thrombotic Strategies in Diabetes from THEMIS and THEMIS PCI	Philippe Gabriel Steg, MD	

	SATURDAY A	AUGUST 22, 2020 (cont.)
12:40PM 12:45PM 1:15PM	AWARD PRESENTATION "LUMINARY IN CARDIOMETABOLIC MEDICINE" Presented by: Deepak L. Bhatt, MD • Mikhail N. Kosiborod, MD • Yehuda Handelsman, MD KEY NOTE: SGLT2i and the Birth of 2 PARADIGM SHIFTS in Clinical Care LIVE Q&A	Eugene Braunwald, MD
1:30PM - 2:15PM	PRODUCT THEATER Non-CME Industry Supported Session The Continuum of Heart Failure Supported by: Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA	Robert J. Mentz, MD
SESSION 7	PRACTICE RECOMMENDATIONS IN DIABETES & ASCVD — AN UPDATE Chairs: Lawrence A. Leiter, MD ● Sergio Fazio, MD, PhD	
2:15pm — 2:30pm 2:30pm — 2:45pm 2:45pm — 3:00pm 3:00pm — 3:15pm 3:15pm — 3:35pm	Contemporary Lipid Management Recommendations in the Prevention of CVD ESC/EASD 2019 CVD in DM Guidelines ADA-EASD Practice Recommendations 2019 Update AACE DM & Lipids Practice Recommendations Panel Discussion & Live Q&A	Christie M. Ballantyne, MD Peter J. Grant, MD David A. D'Alessio, MD Yehuda Handelsman, MD
CME SUPPORTED SYM	APOSIUM: THE PREVENTION AND MANAGEMENT OF HEART FAILURE Chairs: Yehuda Handelsman, MD • Javed Butler, MD 3:35pm — 3:40pm Introduction	BY: ASTRAZENECA
	3:40pm — 4:20pm Epidemiology and Pathophysiology of HF 4:00pm — 4:20pm Preventing HF & HF Adverse Outcomes: A Look at the Evidence 4:20pm — 4:40pm The Present and Future Management of HFrEF and HFpEF 4:40pm — 4:55pm Panel Discussion: Practical Management of HF — Case-Based Panel: Biykem Bozkurt, MD, PhD • Yehuda Handelsman, MD • Mikhail N. Kosiborod, MD Christian W. Mende, MD • Muthiah Vaduganathan, MD Moderator: Javed Butler, MD	Mikhail N. Kosiborod, MD Javed Butler, MD Biykem Bozkurt, MD, PhD
	4:55pm — 5:15pm Live Q&A	
5:15PM - 6:15PM	DAY 2 SUMMARY, LIVE Q&A Panel: Javed Butler, MD • Daniel Einhorn, MD • Yehuda Handelsman, MD	 Mikhail Kosiborod, MD
	Lawrence Leiter, MD • Norman Lepor, MD • Christian Mende, MD	
	Lawrence Leiter, MD ● Norman Lepor, MD ● Christian Mende, MD SUN	DAY AUGUST 23, 2020
SESSION 8	Lawrence Leiter, MD ● Norman Lepor, MD ● Christian Mende, MD	
SESSION 8 10:00am — 10:20am 10:20am — 10:40am 10:40am — 11:00am 11:00am — 11:20am 11:20am — 11:40am	Lawrence Leiter, MD • Norman Lepor, MD • Christian Mende, MD SUN MANAGEMENT OF HYPERGLYCEMIA TO IMPROVE OUTCOMES	
10:00am — 10:20am 10:20am — 10:40am 10:40am — 11:00am 11:00am — 11:20am	Lawrence Leiter, MD • Norman Lepor, MD • Christian Mende, MD MANAGEMENT OF HYPERGLYCEMIA TO IMPROVE OUTCOMES Chairs: George Grunberger, MD • Daniel Einhorn, MD Preventing Diabetes to Prevent CVD: Is it Chicken or Egg? (or Turkey?!) Managing Hyperglycemia in T2DM with Class 4-5 CKD The Combination of SGLT2i and GLP1-ra's Impact on CVD Adjunctive Therapies for Type 1 Diabetes: Thinking Beyond Glucose Control	DAY AUGUST 23, 2020 Silvio E. Inzucchi, MD Vivian A. Fonseca, MD Ralph A. DeFronzo, MD
10:00am — 10:20am 10:20am — 10:40am 10:40am — 11:00am 11:00am — 11:20am 11:20am — 11:40am	SUN MANAGEMENT OF HYPERGLYCEMIA TO IMPROVE OUTCOMES Chairs: George Grunberger, MD ● Daniel Einhorn, MD Preventing Diabetes to Prevent CVD: Is it Chicken or Egg? (or Turkey?!) Managing Hyperglycemia in T2DM with Class 4-5 CKD The Combination of SGLT2i and GLP1-ra's Impact on CVD Adjunctive Therapies for Type 1 Diabetes: Thinking Beyond Glucose Control Panel Discussion & Live Q&A THE TREATMENT OF DIABETES	DAY AUGUST 23, 2020 Silvio E. Inzucchi, MD Vivian A. Fonseca, MD Ralph A. DeFronzo, MD
10:00am — 10:20am 10:20am — 10:40am 10:40am — 11:00am 11:00am — 11:20am 11:20am — 11:40am SESSION 9 DEBATE: EARLY COME 11:40am — 12:00pm 12:00pm — 12:20pm	MANAGEMENT OF HYPERGLYCEMIA TO IMPROVE OUTCOMES Chairs: George Grunberger, MD • Daniel Einhorn, MD Preventing Diabetes to Prevent CVD: Is it Chicken or Egg? (or Turkey?!) Managing Hyperglycemia in T2DM with Class 4-5 CKD The Combination of SGLT2i and GLP1-ra's Impact on CVD Adjunctive Therapies for Type 1 Diabetes: Thinking Beyond Glucose Control Panel Discussion & Live Q&A THE TREATMENT OF DIABETES Chairs: Ralph A. DeFronzo, MD • Vivian A. Fonseca, MD BINATION VS SEQUENTIAL THERAPY - IMPACT ON DM & CVD Sequential Therapy Early Combination Therapy	Silvio E. Inzucchi, MD Vivian A. Fonseca, MD Ralph A. DeFronzo, MD Richard E. Pratley, MD David M. Nathan, MD Stefano Del Prato, MD
10:00am — 10:20am 10:20am — 10:40am 10:40am — 11:00am 11:00am — 11:20am 11:20am — 11:40am SESSION 9 DEBATE: EARLY COME 11:40am — 12:00pm 12:00pm — 12:20pm 12:20pm — 12:45pm	MANAGEMENT OF HYPERGLYCEMIA TO IMPROVE OUTCOMES Chairs: George Grunberger, MD • Daniel Einhorn, MD Preventing Diabetes to Prevent CVD: Is it Chicken or Egg? (or Turkey?!) Managing Hyperglycemia in T2DM with Class 4-5 CKD The Combination of SGLT2i and GLP1-ra's Impact on CVD Adjunctive Therapies for Type 1 Diabetes: Thinking Beyond Glucose Control Panel Discussion & Live Q&A THE TREATMENT OF DIABETES Chairs: Ralph A. DeFronzo, MD • Vivian A. Fonseca, MD SINATION VS SEQUENTIAL THERAPY - IMPACT ON DM & CVD Sequential Therapy Early Combination Therapy Panel, Q&A, Audience Voting PRODUCT THEATER Non-CME Industry Supported Session The Next Horizon in the Heart Failure Treatment Paradigm for Patients with HFrEF: Results of the Landmark DA	Silvio E. Inzucchi, MD Vivian A. Fonseca, MD Ralph A. DeFronzo, MD Richard E. Pratley, MD David M. Nathan, MD Stefano Del Prato, MD
10:00am — 10:20am 10:20am — 10:40am 10:40am — 11:00am 11:00am — 11:20am 11:20am — 11:40am SESSION 9 DEBATE: EARLY COME 11:40am — 12:00pm 12:00pm — 12:20pm 12:20pm — 12:45pm 12:45PM — 1:30PM	SUN MANAGEMENT OF HYPERGLYCEMIA TO IMPROVE OUTCOMES Chairs: George Grunberger, MD • Daniel Einhorn, MD Preventing Diabetes to Prevent CVD: Is it Chicken or Egg? (or Turkey?!) Managing Hyperglycemia in T2DM with Class 4-5 CKD The Combination of SGLT2i and GLP1-ra's Impact on CVD Adjunctive Therapies for Type 1 Diabetes: Thinking Beyond Glucose Control Panel Discussion & Live Q&A THE TREATMENT OF DIABETES Chairs: Ralph A. DeFronzo, MD • Vivian A. Fonseca, MD SINATION VS SEQUENTIAL THERAPY - IMPACT ON DM & CVD Sequential Therapy Early Combination Therapy Panel, Q&A, Audience Voting PRODUCT THEATER Non-CME Industry Supported Session The Next Horizon in the Heart Failure Treatment Paradigm for Patients with HFrEF: Results of the Landmark DA Supported by: AstraZeneca HEART IN DIABETES WITH JACC	Silvio E. Inzucchi, MD Vivian A. Fonseca, MD Ralph A. DeFronzo, MD Richard E. Pratley, MD David M. Nathan, MD Stefano Del Prato, MD

SESSION 11	HEART FAILURE: STATE-OF-THE-ART Chairs: Matthew J. Budoff, MD • Mansoor Husain, MD		
3:10pm — 3:30pm 3:30pm — 3:50pm 3:50pm — 4:10pm 4:10pm — 4:30pm 4:30pm — 5:00pm	Impact of Blood Pressure Variability on CHF HF in DM - Is it Morbidity Not Mortality We Need to Focus on? Physiologic Monitoring of Heart Failure DAPA-HF and Next Steps with SGLT2 Inhibitors in Heart Failure Panel Discussion & Live Q&A	Peter Reaven, MD Mark Kearney, MD Robert J. Chilton, DO John McMurray, MD	
5:00PM - 6:00PM	DAY 3 SUMMARY, LIVE Q&A Panel: Matthew Budoff, MD • Ralph DeFronzo, MD • Vivian Fonseca, MD • Yehuda Handelsman, MD • Mikhail Kosiborod, MD • Muthiah Vaduganathan, MD		
	MONE	DAY, AUGUST 24, 2020	
SESSION 12	GLP1-RA IN ASCVD & THE KIDNEY Chairs: Richard E. Pratley, MD • Matthew R. Weir, MD		
10:00am — 10:20am 10:20am — 10:40am 10:40am — 10:55am 10:55am — 11:15am	Mechanistic Insights into Cardiovascular Effects of GLP1-ra GLP1-ra Impact on the Kidney Role of GLP1-ra in Trials in HF Patients Panel Discussion & Live Q&A	Nikolaus Marx, MD Mark E. Cooper, AO, PhD Javed Butler, MD	
SESSION 13	THE KIDNEY & THE HEART Chairs: Christian W. Mende, MD • Robert J. Chilton, DO		
11:15am — 11:35am 11:35am — 11:55am 11:55am — 12:15pm 12:15pm — 12:35pm 12:35pm — 1:00pm	The Role of Sodium Restriction in HF in Type 2 Diabetes Effect of SGLT2i on BP and CKD Progression: Is it Dependent or Independent of BP? How Do SGLT2i Reduce Cardiorenal Outcomes and Atrial Fibrillation Impact of Kidney Function on Mortality in the CVOTs Panel Discussion & Live Q&A	Jeffrey Testani, MD Matthew R. Weir, MD Subodh Verma, MD, PhD George L. Bakris, MD	
1:00PM - 1:45PM	PRODUCT THEATER Non-CME Industry Supported Session Atherosclerotic Cardiovascular Disease (ASCVC) in Diabetes: Identifying High Risk and Reducing the Burden of Ele Supported by: Novartis	evated LDL-C Levels Speaker: TBD	
SESSION 14	TECHNOLOGY & DIGITAL HEALTH Chair: Christos S. Mantzoros, MD, PhD		
1:45pm — 2:05pm 2:05pm — 2:25pm 2:25pm — 2:45pm 2:45pm — 3:00pm	Artificial Intelligence in the Future Management of Cardiovascular Disease and Diabetes The Implication of Digital Health for Cardiometabolic Conditions Is There an App for That? Role of Devices on Diabetes and CVD Management Panel Discussion & Live Q&A	Irving K. Loh, MD Michael P. Snyder, PhD George Grunberger, MD	
SESSION 15	THE LIVER & THE HEART Chair: Derek LeRoith, MD, PhD		
3:00pm — 3:20pm 3:20pm — 3:40pm 3:40pm — 3:55pm	NAFLD & the Heart as a Part of the Spectrum of Cardiometabolic Risk Emerging Management Options for NAFLD/NASH - Impact on Cardiometabolic Outcomes Panel Discussion & Live Q&A	Laurence Sperling, MD Christos S. Mantzoros, MD, PhD	
3:55pm — 4:55pm	ABSTRACT ORAL PRESENTATIONS 2020 Abstract Committee: George Grunberger, MD Chair • Zachary T. Bloomgarden, MD • Matthew J. Budoff, MD Vivian A. Fonseca, MD • Norman E. Lepor, MD • Derek LeRoith, MD, PhD • Laurence Sperling, MD Abstracts will be published in American Heart Journal Editor-in-Chief: Daniel Mark, MD, MPH		
4:55pm — 5:00pm	ORAL ABSTRACT WINNERS AWARD PRESENTATION		
5:00PM - 6:00PM	DAY 4 SUMMARY, LIVE Q&A Panel: Ralph DeFronzo, MD • George Grunberger, MD • Yehuda Handelsm Christian Mende, MD • Matthew Weir, MD	nan, MD • Derek LeRoith, MD, PhD •	



Yehuda Handelsman, MD FACP, FNLA, FASPC, MACE

Chair & Program Director 4th Heart in Diabetes Medical Director & Principal Investigator The Metabolic Institute of America Tarzana, California



Mikhail N. Kosiborod MD, FACC, FAHA

Chair & Program Director
4th Heart in Diabetes
Professor of Medicine
Saint Luke's Mid America Heart Institute
University of Missouri-Kansas City
School of Medicine
Kansas City, Missouri



George L. Bakris, MD, MA Hon. DSc, FASN, FAHA

Professor of Medicine Director, AHA Comprehensive Hypertension Center The University of Chicago Medicine Chicago, Illinois



Christie M. Ballantyne, MD FACP, FACC

Chief, Sections of Cardiology and Cardiovascular Research Professor, Departments of Medicine Genetics and Physiology Director, Center for Cardiometabolic Disease Prevention Baylor College of Medicine Houston, Texas



Richard C. Becker, MD, FAHA

Professor of Medicine
Director, Division of Cardiovascular Health
and Diseases
Director and Physician-in-Chief
University of Cincinnati Heart
Lung & Vascular Institute
University of Cincinnati
College of Medicine
Cincinnati, Ohio



Joshua Beckman, MD, MS

Professor of Medicine
Director, Vascular Medicine Section
Vanderbilt Translational and Clinical
Cardiovascular Research Center (VTRACC)
Vanderbilt University Medical Center
Nashville, Tennessee



Deepak L. Bhatt, MD, MPH FACC, FAHA, FSCAI, FESC

Executive Director of Interventional Cardiovascular Programs, Brigham and Women's Hospital Heart & Vascular Center Professor of Medicine, Harvard Medical School Boston, Massachusetts



Zachary Bloomgarden, MD MACE

Editor, the Journal of Diabetes www.jdiabetes.com, Clinical Professor Icahn School of Medicine at Mount Sinai New York, New York



Biykem Bozkurt, MD, PhD FHFSA, FACC, FAHA, FESC FACP

President, Heart Failure
Society of America
The Mary and Gordon Cain Chair
"Tex" and Deborah Moncrief, Jr., Chair
Professor of Medicine
Medical Care Line Executive
DeBakey VA Medical Center
Director, Winters Center for
Heart Failure Research
Associate Director
Cardiovascular Research Institute
Vice-Chair of Medicine
Baylor College of Medicine
Houston, Texas



Eugene Braunwald, MD

Distinguished Hersey Professor of Medicine Harvard Medical School Founding Chairman, TIMI Study Group Brigham and Women's Hospital Boston, Massachusetts



Matthew J. Budoff, MD FACC, FAHA

Professor of Medicine
David Geffen School of Medicine at UCLA
Endowed Chair of Preventive Cardiology
Program Director, Director of Cardiac CT
Lundquist Institute
Harbor-UCLA Medical Center
Division of Cardiology
Los Angeles, California



Javed Butler, MD, MPH, MBA

Patrick H. Lehan Chair in Cardiovascular Research Professor and Chairman, Department of Medicine University of Mississippi Medical Center Jackson, Mississippi



Robert J. Chilton, DO, FACP, FACC, FAHA, MACOI, FASCAI

Professor of Medicine Department of Medicine Division of Cardiology The University of Texas Health Science Center San Antonio, Texas



David J. Cohen, MD, MSc

Professor of Medicine University of Missouri-Kansas City Kansas City, Missouri



Mark E. Cooper, MB BS, PhD, FRACP

Head, Department of Diabetes Central Clinical School Monash University Senior Endocrinologist Alfred Health Clinic Melbourne, Australia



David A. D'Alessio, MD

Professor of Medicine Chief, Division of Endocrinology Metabolism and Nutrition Associate Director, Duke Molecular Physiology Institute Durham, North Carolina



Michael H. Davidson, MD FACC, FACP, FNLA

Professor, Director of the Lipid Clinic The University of Chicago Pritzker School of Medicine Chicago, Illinois



Ralph A. DeFronzo, MD

Professor of Medicine Chief, Diabetes Division University of Texas Health Science Center at San Antonio (UTHSCSA) Deputy Director, Texas Diabetes Institute San Antonio, Texas





Stefano Del Prato, MD
Professor of Endocrinology
and Metabolism
Chief of the Section of Dighetes

Chief of the Section of Diabetes University of Pisa, School of Medicine Pisa, Italy



Daniel Einhorn, MD FACP, FACE

President, Diabetes and Endocrine Associates Medical Director Scripps Whittier Diabetes Institute Past President, American Association of Clinical Endocrinology Past President, American College of Endocrinology (ACE) Associate Editor, Journal of Diabetes La Jolla, California



Michael E. Farkouh, MD MSc, FRCPC, FACC, FAHA

Peter Munk Chair in
Multinational Clinical Trials
Director, Heart & Stroke Richard Lewar
Centre of Excellence,
University of Toronto
Vice-Chair Research & Professor of
Medicine, Department of Medicine
University of Toronto
Toronto, Ontario, Canada



Sergio Fazio, MD, PhD

The William and Sonja Connor Chair of Preventive Cardiology Professor of Medicine and Physiology & Pharmacology Director, Center for Preventive Cardiology Knight Cardiovascular Institute Oregon Health & Science University Portland, Oregon



Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology Assistant Dean for Clinical Research Tullis Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology Tulane University Health Sciences Center New Orleans, Louisiana



Peter J. Grant, MD FRCP, FMedSci

Professor of Medicine and Diabetologist Honorary Consultant Physician, Leeds Teaching Hospitals NHS Trust Division of Cardiovascular & Diabetes Research University of Leeds Leeds, United Kingdom



George Grunberger, MD FACP, FACE

Chairman, Grunberger Diabetes Institute
Clinical Professor, Internal Medicine and
Molecular Medicine & Genetics
Wayne State University
School of Medicine
Professor, Internal Medicine
Oakland University William Beaumont
Visiting Professor, Internal Medicine
First Faculty of Medicine
Charles University,
Prague, Czech Republic
Bloomfield Hills, Michigan



Daniel Gudbjartsson, PhD

V.P. of Statistics deCODE Genetics Reykjavik, Iceland



Mansoor Husain, BSc FRCPC. MD

Executive Director,
Ted Rogers Centre for Heart Research
Director, Toronto General Hospital
Research Institute,
University Health Network
Professor, Department of Medicine,
University of Toronto
Senior Scientist, Toronto General Hospital
Research Institute,
University Health Network
Toronto, Canada



Silvio E. Inzucchi, MD

Professor of Medicine
Yale School of Medicine
Clinical Chief, Endocrinology and
Medical Director
Yale Diabetes Center
Yale-New Haven Hospital
New Haven, Connecticut



Paul S. Jellinger, MD, MACE

Professor of Clinical Medicine Voluntary Faculty University of Miami Miller School of Medicine The Center for Diabetes & Endocrine Care Past President, AACE & ACE Hollywood, Florida



Mark Kearney, MBChB MRCP, MD

British Heart Foundation Professor of Cardiovascular and Diabetes Research Leeds Institute of Cardiovascular & Metabolic Medicine Dean of the School of Medicine University of Leeds Leeds, United Kingdom



Lawrence A. Leiter, MDCM FRCPC, FACP, FACE, FAHA

Associate Scientist, Li Ka Shing Knowledge Institute Director, Lipid Clinic Associate Director, Clinical Nutrition and Risk Factor Modification Centre St. Michael's Hospital Professor, Medicine and Nutritional Sciences University of Toronto Toronto. Canada



Norman E. Lepor, MD, FACC

Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Attending Cardiologist at the Smidt
Cedars-Sinai Heart Institute
Director of Clinical Research
Westside Medical Associates of LA
Co-Director of Cardiovascular Imaging
Westside Medical Imaging in Beverly Hills
Los Angeles, California



Derek LeRoith, MD, PhD FACP

Professor of Medicine
Director of Research
Division of Endocrinology
Diabetes & Bone Disease
Department of Medicine
Icahn School of Medicine at Mt. Sinai
New York. New York



Alice H. Lichtenstein, D.Sc.

Gershoff Professor of Nutrition
Science and Policy
Director and Senior Scientist
Cardiovascular Nutrition Laboratory
Tufts University
JM USDA Human Nutrition Research
Center on Aging
Executive Editor, Tufts Health and
Nutrition Letter
Boston, Massachusetts



Myra A. Lipes, MD

Assistant Professor, Medicine Harvard Medical School Assistant Professor, Medicine, Brigham And Women's Hospital Investigator, Research Division Joslin Diabetes Center Boston, Massachusetts



Irving Kent Loh MD FACC, FAHA, FCCP, FACP

Chief Medical Officer and Co-Founder, INFERMEDICA
Ventura Heart Institute
Chair, Technology & Innovation,
California Chapter,
American College of Cardiology
Member, Al4H, International
Telecommunication Union, World Health
Organization/UN
Adjunct Lecturer, Department of
Medicine, Stanford University
School of Medicine
Thousand Oaks, California



Julie A. Lovshin, MD, PhD FRCPC

Clinician Scientist
Assistant Professor of Medicine
Division of Endocrinology & Metabolism
University of Toronto
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada



Gina P. Lundberg, MD FACC, FAHA

Clinical Director Emory Women's Heart Center Associate Professor of Medicine Emory University School of Medicine Division of Cardiology Atlanta, Georgia



Christos S. Mantzoros, MD DSc, PhD h.c. mult.

Professor of Medicine
Harvard Medical School and Boston
University School of Medicine
Chief of Endocrinology,
Diabetes and Metabolism
Boston VA Healthcare System
Director of Human Nutrition, Beth Israel
Deaconess Medical Center
Editor-in-Chief, Metabolism
Clinical & Experimental
Boston, Massachusetts



Nikolaus Marx, MD FESC, FAHA

Professor of Medicine / Cardiology Head of the Department of Internal Medicine University Hospital RWTH Aachen Aachen, Germany



John McMurray, BSC (Hons) MB ChB (Hons), MD, FRCP FESC, FACC, FAHA, FRSE FMedSci, OBE

Professor of Medical Cardiology and Deputy Director (Clinical) Institute of Cardiovascular and Medical Sciences Honorary Consultant Cardiologist Queen Elizabeth University Hospital Glasaow, Scotland



Christian W. Mende, MD FACP, FACN, FASN, FASH, FAHA

Clinical Professor of Medicine University of California San Diego La Jolla, California



Robert J. Mentz, MD FACC, FAHA, FHFSA

Associate Professor of Medicine Chief, Heart Failure Section Associate Program Director, Duke Cardiovascular Disease Fellowship Duke University Medical Center and Duke Clinical Research Institute Durham, North Carolina



David M. Nathan, MD

Director, Diabetes Center and Clinical Research Center Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts



Steven E. Nissen, MD, MACC

Chief Academic Officer
Heart and Vascular Institute
Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner
School of Medicine
at Case Western Reserve University
Cleveland, Ohio



Neha J. Pagidipati, MD, MPH

Assistant Professor of Medicine,
Division of Cardiology
Director, Duke Cardiometabolic
Prevention Program
Associate Program Director
Cardiology Fellowship
Associate Program Director
DCRI Research Fellowship
Duke Clinical Research Institute
Duke University Medical School
Durham, North Carolina



Richard E. Pratley, MD

Samuel E. Crockett
Chair in Diabetes Research
Medical Director, AdventHealth
Diabetes Institute
Senior Investigator and
Diabetes Program Lead
AdventHealth Translational
Research Institute
Orlando, Florida





Kausik Ray, BSc(hons) MBChB, MD, MPhil (Cantab) FRCP (Lon), FRCP (Ed), FACC FESC, FAHA

Professor of Public Health
Consultant Cardiologist
Deputy Director of The Imperial Clinical
Trials Unit Head of Commercial Trials
Department of Public
Health & Primary Care
School of Public Health, Imperial College
NIHR ARC National Lead of
Cardiovascular Disease
EAS President Elect
London, United Kingdom



Peter Reaven, MD

Professor of Clinical Medicine University of Arizona Director, Diabetes Program Carl T. Hayden VAMC (111E) Research Professor College of Health Solutions Arizona State University Phoenix, Arizona



Jennifer G. Robinson, MD, MPH

Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center Carver College of Medicine University of Iowa Iowa City, Iowa



Benjamin M. Scirica, MD, MPH

Associate Professor of Medicine, Harvard Medical School Associate Physician Brigham and Women's Hospital Senior Investigator, TIMI Study Group Boston, Massachusetts



Michael P. Snyder, PhD

Professor and Chair of Genetics Director, Center for Genomics and Personalized Medicine Stanford University School of Medicine Stanford, California



Laurence Sperling, MD FACC, FAHA, FACP, FASPC

Katz Professor in Preventive Cardiology Director of the Emory Heart Disease Prevention Center Professor of Global Health Hubert Department of Global Health Rollins School of Public Health at Emory University Atlanta, Georgia



Philippe Gabriel Steg, MD FESC, FACC

Chief, Department of Cardiology Hôpital Bichat, Assistance Publique-Hôpitaux de Paris Vice President Board of the Assistance Publique-Hôpitaux de Paris Professor of Cardiology, Université Paris - Diderot Director, "Clinical Research in Atherothrombosis" Research Team Coordinator of the iVASC (InnoVations in Atherothrombosis SCience) RHU research consortium Chair of the FACT Chairman of the French National University Council Paris, France



Jeffrey Testani, MD, MTR

Associate Professor Director of Heart Failure Research, Section of Cardiovascular Medicine Yale University School of Medicine New Haven, Connecticut



Muthiah Vaduganathan, MD, MPH

Cardiologist, Brigham and Women's Hospital Instructor of Medicine Harvard Medical School Boston, Massachusetts



Subodh Verma, MD, PhD FRCSC, FAHA

Cardiac Surgeon
Professor of Surgery and
Pharmacology & Toxicology
University of Toronto
Canada Research Chair in
Cardiovascular Surgery
Division of Cardiac Surgery
St. Michael's Hospital
Toronto, Ontario, Canada



Allen Wang, MD

Duke Center for Atrial Fibrillation Department of Medicine Duke University Medical Center Durham, North Carolina



Matthew R. Weir, MD

Professor and Chief Nephrology Division Department of Medicine University of Maryland School of Medicine Baltimore, Maryland

HEART IN DIABETES PROGRAM COMMITTEE

Yehuda Handelsman, MD, Chair • Mikhail N. Kosiborod, MD, Chair • Deepak L. Bhatt, MD • Zachary T. Bloomgarden, MD • Biykem Bozkurt, MD, PhD

Matthew J. Budoff, MD • Javed Butler, MD • David Cherney, MD, PhD • Robert J. Chilton, DO • Mark E. Cooper, AO, PhD

Michael H. Davidson, MD • Ralph A. DeFronzo, MD • Daniel Einhorn, MD • Michael E. Farkouh, MD • Sergio Fazio, MD, PhD • Vivian A. Fonseca, MD

Peter J. Grant, MD • George Grunberger, MD • Silvio E. Inzucchi, MD • Paul S. Jellinger, MD • Mark Kearney, MD • Lawrence A. Leiter, MDCM

Norman E. Lepor, MD • Derek LeRoith, MD, PhD • Christos S. Mantzoros, MD, DSc, PhD • Nikolaus Marx, MD • Darren K. McGuire, MD

Christian W. Mende, MD • Richard E. Pratley, MD • Kausik Ray, MD • Peter Reaven, MD • Laurence Sperling, MD • Matthew R. Weir, MD • Renee S. Asp, BS

ATTENDANCE IS FREE!

Free Registration • Free CME

www.heartindiabetes.com/registration

Email: info@tmioa.com

To register by phone: (818) 342-1889

CME ACCREDITATION

This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Designation Statement

The PESI Inc. designated this live activity for a maximum of 28 AMA PRA Category 1 Credit(s) $^{\text{TM}}$. Physicians should only claim credit commensurate with the extent of their participation in the activity.

MOC Points with ABIM

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 28 MOC points of Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

International CME

International Physicians are formally eligible for AMA PRA Category 1 Credit™.

Physician Assistants

AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit $^{\text{TM}}$ for the PRA from organizations accredited by ACCME.

Nurses

For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CA Nurses

Aspen CME Services is approved by the California Board of Registered Nursing, provider number CEP14739, designated the 4th HiD for approximately 28 contact hours.

Pharmacists

For the purpose of recertification, the American Council of Pharmacy Education accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CDE

The National Certification Board for Diabetes Educators recognizes courses sponsored by PESI Inc. as approved ACCME provider. This course qualifies for 28 continuing education hours.

Registered Dietitian

For the purpose of recertification, the Commission on Dietetic Registration recognizes courses accredited with AMA PRA Category 1 Credit™.

Satisfactory Completion for credits

All attendees must have completed and turned in a course attendance/ evaluation form prior to leaving the conference. Each session claimed for credit must be attended in its entirety.

ENDORSING ORGANIZATIONS:











American Society of Endocrine Physician Assistants



American Society for Nutrition

Excellence in Nutrition Research and Practice



















SAVE THE DATE 5th ANNUAL | HEART IN DIABETES

Live CME Conference | June 18-20, 2021 Grand Hyatt, New York City



2020 MEDIA PARTNERS







THE LANCET Diabetes & Endocrinology







Journal of Diabetes



BENTHAM SCIENCE





Bentham Science Publishers is a major STM journal publisher of 130 plus print and online journal. Out of these, 40 journals have already registered good IMPACT FACTORS as per Journal Chation Reports® 2017. These titles have extensive readership mostly in Europe and North America. For a detailed profile please visit our website at http://www.benthamscience.com. Besides, Bentham Science publishes abloaks in all areas of Science. Technology and Medicine. Our eBooks provide professionals, accomplicing, corporate researchers, graduates and undergraduates worldwide with the most current information in their subject areas of interest. Our eBooks are also available in the ePub and Kindle formats besides the PDF edition here http://ebooks.benthamscience.com/. Bentham Science is offering 20% discounts on purchasing eBooks and subscriptions on Journals to delegates attending the conference. TO AWAIL, QUOTE "BSPCNF2019" at www.eureksaslest.com or email at marketing@benthamscience.gog. For more information glick.here.





Cardiology Advisor





Diabetes & Vasular Disease SAGE Research



Built on an ethos of openness, Hindawi is passionate about working with the global academic community to promote open scholarl research to the world.

Explore our Open Access medical journals in cardiology, diabetes, obesity and nutrition. Looi out for an exclusive Article Processing Charge (APC) discount during the conference.

Hindawi View our medical journals >>







Physician's Weekly

For additional information on

REGISTRATION • SUPPORT • EXHIBITS

(818) 342-1889 | info@tmioa.com | www.heartindiabetes.com